质子治疗头颈癌口腔黏膜炎的质子特异性剂量与辐射质量约束
研究在迈阿密大学纳入79例接受IMPT与94例接受VMAT光子治疗的头颈癌患者,评估口腔黏膜炎(RIOM)与口腔接受的物理剂量、辐射质量(微剂量学)及体积效应的关系。VMAT的RIOM发生率显著更高(84%,其中G2+G3占68%),IMPT为56%(G2+G3占33%)。研究提出不依赖恒定RBE的质子特异性剂量-体积约束,对G2+G3毒性判别良好(AUC=0.81)。
要点
- VMAT的RIOM显著高于IMPT:84%(G2+G3 68%)对56%(G2+G3 33%)。
- 剂量与体积是黏膜炎主要驱动因素,辐射质量影响严重程度。
- 新的IMPT剂量-体积耐受低于VMAT,且随y¯D>5 keV/μm时辐射质量升高而降低。
核心结论
- 将剂量、器官体积与辐射质量整合进质子特异性约束、不依赖恒定临床RBE或光子衍生耐受,可改善毒性判别并为降低IMPT的G2+G3 RIOM提供临床可行框架。
研究设计与样本
- 单中心研究,纳入79例接受IMPT与94例接受VMAT光子治疗的头颈癌患者,采集口腔物理剂量、辐射质量(微剂量学描述)及患者个体信息。
主要发现
- VMAT组RIOM发生率84%(G2+G3占68%),IMPT组56%(G2+G3占33%),VMAT与显著更高的RIOM分级相关。
- 剂量与体积是黏膜炎的主要驱动因素,辐射质量影响其严重程度。
- 新IMPT剂量-体积耐受一致低于VMAT,且在y¯D>5 keV/μm时随辐射质量升高而降低。
- 约束对G2+G3毒性判别良好(AUC=0.81),模型模拟显示完全依从下RIOM可由33%降至20%。
关键数值与推荐
- 新的IMPT剂量-体积耐受一致低于VMAT耐受,并随y¯D>5 keV/μm时辐射质量升高而降低。
- G2+G3毒性判别AUC=0.81;完全依从模拟下RIOM由33%降至20%。
临床怎么用
- 对IMPT头颈癌患者,可结合口腔剂量、体积效应与微剂量学辐射质量制定质子特异性约束,替代基于RBE=1.1的光子衍生均值剂量约束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiation-induced oral mucositis (RIOM) is one of the most frequent and impairing toxicities in head and neck cancer patients. The current clinical mitigation strategy for RIOM relies on photon-derived dosimetric constraints normalized by the proton generic relative biological effectiveness (RBE) of 1.1, and applied to the mean dose at the oral cavity. The approach neglects any dependence of toxicity on organ volume effects and radiation quality. In the present study, we provide a comprehensive characterization of RIOM in proton therapy patients, and develop proton-specific constraints to reduce RIOM which do not rely on RBE. METHODS: We evaluated RIOM in 79 patients treated with Intensity Modulated Proton Therapy (IMPT) and 94 patients with Volumetric Modulated Arc Therapy (VMAT) photon therapy at the University of Miami. For each patient, we collected the physical dose and radiation quality received by the oral cavity, as well as patient-specific information. We used microdosimetry to describe radiation quality. RESULTS: VMAT is associated to a significantly higher grade of RIOM, with 84% of cases (68% G2 + G3), compared to 56% for IMPT (33% G2 + G3). Dose and volume are the primary drivers of mucositis, with radiation quality influencing severity. The new IMPT dose-volume tolerances are consistently lower than VMAT, and decrease with increasing radiation quality for y¯D > 5 keV/μm. The constraints demonstrated good discrimination of G2 + G3 toxicity (AUC = 0.81), and model-based simulations projected a reduction of RIOM from 33% to 20% under full compliance. CONCLUSIONS: Integrating dose, organ volume, and radiation quality into proton-specific constraints without relying on a constant clinical RBE or photon-derived tolerances improves toxicity discrimination and provides a clinically attainable framework for reducing G2 + G3 RIOM in IMPT.
引用
- Cartechini G, Schnelzauer L, Cordoni FG, et al. Proton-specific dose and radiation quality constraints to reduce acute oral mucositis in head and neck cancer patients. Radiother Oncol. 2026. PMID: 41946421. doi:10.1016/j.radonc.2026.111522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。